Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Reneo Pharmaceuticals, Inc. (RPHM) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Investor presentation
Docs: "Reneo Pharmaceuticals, Inc. KOL Event Presentation"
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "RENEO PHARMACEUTICALS, INC. Consolidated Balance Sheets June 30, 2023 December 31, 2022 Assets Current assets: Cash and cash equivalents $ 9,081 $ 19,927 Short-term investments 133,596 81,246 Prepaid expenses and other current assets 3,643 5,180 Total current assets 146,320 106,353 Property and equipment, net 554 453 Right-of-use assets 1,086 1,292 Other non-current assets 79 84 Total assets $ 148,039 $ 108,182 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 1,828 $ 1,893 Accrued expenses 11,592 4,827 Operating lease liabilities, current portion 318 404 Total current liabilities 13,738 7,124 Operating lease liabilities, less current portion 897 1,059 Performance award 876 29 Total liabilities 15,511 8,212 Commitments and contingencies Stockholders’ equity: Comm..."
06/07/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/30/2023 SC 13D/A RiverVest Venture Fund III, L.P. reports a 7.5% stake in RENEO PHARMACEUTICALS, INC.
05/15/2023 SC 13D/A Novo Holdings A/S reports a 10.2% stake in Reneo Pharmaceuticals, Inc.
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results • Completed enrollment of the pivotal STRIDE study; topline results anticipated 4Q 2023 • Raised $68.3 million in gross proceeds from a concurrent public offering and private placement IRVINE, Calif., May 11, 2023 -- Reneo Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended March 31, 2023 and provided a business update. “In the first quarter we achieved a key milestone with the completion of enrollment of the pivotal STRIDE study. We have been encouraged by the patient interest in our mavodelpar program, which led to an ov..."
05/09/2023 SC 13D/A Carlyle Group Inc. reports a 8.2% stake in Reneo Pharmaceuticals, Inc.
05/05/2023 8-K Quarterly results
05/04/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/03/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
04/26/2023 ARS Form ARS - Annual Report to Security Holders:
04/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/27/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/27/2023 10-K Annual Report for the period ended December 31, 2022
03/27/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "RENEO PHARMACEUTICALS, INC. Consolidated Balance Sheets December 31, 2022 2021 Assets Current assets: Cash and cash equivalents $ 19,927 $ 124,660 Short-term investments 81,246 23,010 Prepaid expenses and other current assets 5,180 6,064 Total current assets 106,353 153,734 Property and equipment, net 453 212 Right-of-use assets 1,292 — Other non-current assets 84 78 Total assets $ 108,182 $ 154,024 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 1,893 $ 2,022 Accrued expenses 4,827 4,180 Operating lease liabilities, current portion 404 — Total current liabilities 7,124 6,202 Operating lease liabilities, less current portion 1,059 — Other long-term liabilities — 167 Performance award 29 444 Total liabilities 8,212 6,813 Commitments and contingencies Stockholder..."
03/14/2023 8-K Other Events  Interactive Data
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
01/09/2023 8-K Investor presentation
Docs: "Corporate Slide Presentation dated January 2023"
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
Docs: "RENEO PHARMACEUTICALS, INC. Consolidated Balance Sheets September 30, 2022 December 31, 2021 Assets Current assets: Cash and cash equivalents $ 62,132 $ 124,660 Short-term investments 53,948 23,010 Prepaid expenses and other current assets 4,918 6,064 Total current assets 120,998 153,734 Property and equipment, net 241 212 Right-of-use assets 1,186 — Other non-current assets 79 78 Total assets $ 122,504 $ 154,024 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 2,189 $ 2,022 Accrued expenses 6,851 4,180 Operating lease liabilities, current portion 410 — Total current liabilities 9,450 6,202 Operating lease liabilities, less current portion 943 — Other long-term liabilities — 167 Performance award 66 444 Total liabilities 10,459 6,813 Commitments and contingencie..."
09/30/2022 SC 13D/A Novo Holdings A/S reports a 14% stake in Reneo Pharmaceuticals, Inc.
08/11/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/09/2022 8-K Quarterly results
Docs: "RENEO PHARMACEUTICALS, INC. Consolidated Balance Sheets June 30, 2022 December 31, 2021 Assets Current assets: Cash and cash equivalents $ 118,264 $ 124,660 Short-term investments 8,588 23,010 Prepaid expenses and other current assets 5,159 6,064 Total current assets 132,011 153,734 Property and equipment, net 236 212 Right-of-use assets 1,283 — Other non-current assets 78 78 Total assets $ 133,608 $ 154,024 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 1,560 $ 2,022 Accrued expenses 6,367 4,180 Operating lease liabilities, current portion 408 — Total current liabilities 8,335 6,202 Operating lease liabilities, less current portion 1,061 — Other long-term liabilities — 167 Performance award 55 444 Total liabilities 9,451 6,813 Commitments and contingencies St..."
08/02/2022 8-K Quarterly results
06/02/2022 8-K Quarterly results
05/10/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/10/2022 8-K Quarterly results
05/10/2022 EFFECT Form EFFECT - Notice of Effectiveness:
05/02/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
04/22/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy